RT Journal Article SR Electronic T1 Heme induces mRNA expression and activation of tissue factor by TLR4 dependent mechanisms JF medRxiv FD Cold Spring Harbor Laboratory Press SP 2020.10.09.20210336 DO 10.1101/2020.10.09.20210336 A1 B.W. Hounkpe A1 C.R.P. Moraes A1 M.N.N. do Santos A1 F. F. Costa A1 E.V. De Paula YR 2020 UL http://medrxiv.org/content/early/2020/10/13/2020.10.09.20210336.abstract AB Introduction Hemolytic diseases such as Sickle Cell Disease (SCD) are characterized by a natural propensity for both arterial and venous thrombosis. Evidence showing that heme can induce tissue factor (TF) expression in endothelial cells and TF-dependent coagulation activation in animal models of SCD suggest that heme can contribute to hypercoagulability in this condition. We recently demonstrated that heme can induce coagulation activation in whole blood of healthy volunteers in a TF-dependent fashion.Methods Herein, we aimed to evaluate whether this heme-induced coagulation activity was dependent on the expression and/or activation of hematopoietic TF in human mononuclear cells. TF mRNA expression was evaluated by qPCR and TF procoagulant activity was evaluated using a 2-stage assay based on the generation of FXa.Results Heme was capable of inducing TF expression and activation in a TLR4-dependent pathway. This activity was further amplified after TNF-α-priming.Conclusion Our results provide additional evidences on the mechanisms by which heme is involved in the pathogenesis of hypercoagulability in hemolytic diseases.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study was financially supported by the Sao Paulo Research Foundation, grants # 2014/0984-3 and 2015/24666-3; CNPq Brazil, grant # 309317/2016; and Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior - Brasil (CAPES) - Finance Code 001.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was performed in accordance with the Declaration of Helsinki and approved by the Ethics Committee of University of Campinas (CAAE: 46853115.4.0000.5404).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data generated during this study are included in this article.